A Trinity regimen with aflibercept for treatment-naïve neovascular age-related macular degeneration: 2-year outcomes

被引:0
作者
Makiko Wakuta
Nanami Nomi
Tadahiko Ogata
Manami Ota
Chiemi Yamashiro
Makoto Hatano
Ryoji Yanai
Kazuhiro Tokuda
Kazuhiro Kimura
机构
[1] Yamaguchi University Graduate School of Medicine,Department of Ophthalmology
[2] Ube-Kohsan Central Hospital,undefined
[3] JCHO Shimonoseki Medical Center,undefined
来源
Graefe's Archive for Clinical and Experimental Ophthalmology | 2020年 / 258卷
关键词
Neovascular age-related macular degeneration; Pro re nata regimen; Treat and extend regimen; Fixed regimen; Antivascular endothelial growth factor; Aflibercept;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1663 / 1670
页数:7
相关论文
共 193 条
[1]  
Congdon N(2004)Causes and prevalence of visual impairment among adults in the United States Arch Ophthalmol 122 477-485
[2]  
O’Colmain B(2004)Global data on visual impairment in the year 2002 Bull World Health Organ 82 844-851
[3]  
Klaver CC(2006)Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration Retina 26 859-870
[4]  
Klein R(2014)Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies Ophthalmology 121 193-201
[5]  
Muñoz B(2006)Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 1419-1431
[6]  
Friedman DS(2006)Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 1432-1444
[7]  
Kempen J(2012)Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration Ophthalmology 119 2537-2548
[8]  
Taylor HR(2009)A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study Am J Ophthalmol 148 43-58
[9]  
Mitchell P(2013)Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP) Ophthalmology 120 2292-2299
[10]  
Resnikoff S(2015)Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results Ophthalmology 122 2514-2522